GlassScriptPhysician profile
Joshua B Morrison
NPI 1083848956
$2,599.59
in general payments reported to CMS, 2019-2025
27 companies · $19.70 in 2025
The $19.70 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $222 · 2021: $384 · 2022: $640 · 2023: $428 · 2024: $402 · 2025: $19.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $786.56 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $354.25 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Jazz Pharmaceuticals INC. | $188.00 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $166.88 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.39 | 2019-2024 | Ofev, Stiolto Respimat |
| Genzyme Corporation | $126.22 | 2019-2024 | |
| Mylan Specialty L.P. | $104.47 | 2019-2023 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $103.03 | 2020-2022 | |
| Insmed, INC. | $98.67 | 2020-2022 | |
| Genentech USA, INC. | $88.74 | 2019-2024 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $71.46 | 2021-2023 | Glassia |
| Grifols USA, LLC | $70.11 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $48.29 | 2019 | |
| United Therapeutics Corporation | $28.79 | 2024 | Tyvaso |
| Teva Pharmaceuticals USA, INC. | $28.35 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuwellis, INC. | $24.65 | 2023 | Aquadex Smartflow Console |
| Vifor Pharma, INC. | $21.80 | 2024 | Veltassa |
| Livanova USA, INC. | $20.64 | 2023 | Lifesparc |
| Amgen INC. | $19.18 | 2023 | Tezspire |
| Novartis Pharmaceuticals Corporation | $17.62 | 2022 | |
| Mallinckrodt Hospital Products INC. | $17.32 | 2020 | |
| Melinta Therapeutics, LLC | $15.22 | 2019 | |
| Pulmonx Corporation | $15.12 | 2020 | |
| Allergan, INC. | $14.43 | 2019 | |
| Advanced Respiratory, INC | $14.40 | 2020 | |
| Fisher & Paykel Healthcare INC | $13.62 | 2022 | |
| Paratek Pharmaceuticals, INC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.